ITI Pharma and Healthcare Fund
ITI Mutual Fund · Sectoral/Thematic · Regular plan, growth option
| Period | Scheme | Category median | Healthcare & pharma median |
|---|---|---|---|
| 1 month | -3.2% | -5.4% | -3.2% |
| 3 months | 2.1% | -3.1% | 2.7% |
| 6 months | 19.1% | 8.5% | 21.0% |
| Year to date | 12.3% | -2.6% | 16.3% |
| 1 year | 10.4% | 0.0% | 16.0% |
| 3 years (CAGR) | 16.7% | 11.7% | 19.2% |
| 5 years (CAGR) | n/a | 10.6% | 13.7% |
| 7 years (CAGR) | n/a | 15.7% | 23.7% |
| 10 years (CAGR) | n/a | 13.3% | 13.4% |
| Since first NAV (CAGR) | 12.3% | – | – |
“Healthcare & pharma” is MFIC's grouping of Sectoral/Thematic schemes by the theme or index in their names, not an AMFI category.
| Measure | Scheme | Category median |
|---|---|---|
| 1Y rolling median | 13.8% | 9.8% |
| 3Y rolling median | 19.1% | 15.6% |
| 3Y rolling worst | 15.2% | 0.6% |
| 3Y periods positive | 100% | 100% |
| 3Y periods ahead of benchmark | 99% | 71% |
| 5Y rolling median | n/a | 14.2% |
| 5Y rolling worst | n/a | 0.3% |
| 5Y periods ahead of benchmark | n/a | 70% |
Benchmark: Nifty 500 (proxy: Motilal Oswal Nifty 500 Index Fund, price return).
| Measure | Scheme | Category median |
|---|---|---|
| Standard deviation (ann.) | 16.5% | 16.7% |
| Sharpe ratio | 0.71 | 0.34 |
| Sortino ratio | 1.13 | 0.51 |
| Beta | 0.79 | 0.96 |
| Alpha (ann.) | 9.0% | 2.3% |
| Upside capture | 114.08 | 103.56 |
| Downside capture | 76.68 | 96.87 |
| Measure | Scheme | Category median |
|---|---|---|
| Maximum drawdown, full history | −18.5% | −23.7% |
| Maximum drawdown, last 10Y | n/a | −39.3% |
| Maximum drawdown, last 5Y | n/a | −22.8% |
| Current drawdown | −4.4% | −8.8% |
| Recovery time of worst fall | 384 days | – |
Longer histories include more crises, so compare the 5Y and 10Y figures across schemes of different ages.
This scheme invests mainly in the markets below, which are also close to how many of them are benchmarked. Where those markets stand today:
- P/E 40.7
- 1Y +21.5% · 3Y +19.9% p.a. · 5Y +13.1% p.a. (index fund NAV, after costs)
- −3.2% from its 52-week high
- P/E 41.9
- 1Y +12.4% · 3Y n/a p.a. · 5Y n/a p.a. (index fund NAV, after costs)
- −5.0% from its 52-week high (proxy NAV)
- P/E 21.6
- 1Y −3.9% · 3Y +8.9% p.a. · 5Y +8.6% p.a. (index fund NAV, after costs)
- −9.3% from its 52-week high
Index levels and P/E: NSE daily index closing values; gold and silver: IBJA rates; returns: growth NAV of an index fund or ETF tracking the market (AMFI), so they are after that fund's costs. Context only: a market's level or valuation does not tell you how any scheme will perform. Explore all markets.
The Regular plan's expense ratio is 2.59% a year and the Direct plan's 0.89%, a gap of 1.70%; over the last 3 years the Direct plan returned 2.20 percentage points a year more. On a ₹25,000 monthly SIP for 20 years (illustration at 12% a year before costs) the gap adds up to about ₹37,80,090.
With the Regular plan, that cost pays a distributor to help you plan, choose and review funds, and stay invested when markets fall. Whether it is worth it depends on how much of that you will do yourself.
TER: AMFI TER disclosure. Returns: AMFI NAVs. Illustration, not a guaranteed saving or return.
- 1 Oct 2026: TER reduced from 2.62% to 2.59% (AMFI TER disclosure)
| Fund manager | Role | Managing since |
|---|---|---|
| Animesh Singh | Fund manager | 8 May 2026 |
| Nilay Dalal | Fund Manager | 8 May 2026 |
Documents: Scheme Information Document · Scheme Summary Document. Read the scheme documents before investing.
| Measure | Scheme | Category median |
|---|---|---|
| Expense ratio (TER), Regular plan | 2.59% | 2.38% |
| AUM, whole scheme (₹ crore) | 266 | 1,245 |
| Riskometer | Very High | – |
TER: AMFI, TER of MF Schemes. AUM and riskometer: AMFI, Fund Performance, 30 Sep 2026.
| Measure | Scheme | Benchmark / category |
|---|---|---|
| Return, 1 year (AMFI) | 11.9% | 14.7% TRI |
| Return, 3 years (AMFI) | 16.7% | 19.0% TRI |
| Month-ends above category median (3Y CAGR) | 96% | 53% median |
| Month-ends in category top quartile (3Y) | 4% | 24% median |
Official benchmark: NIFTY Healthcare TRI (total return index, as published by AMFI). Category consistency: last 10 years of month-ends, Sectoral/Thematic Regular plans; how it is calculated.
| Year | Scheme | Nifty 500 proxy | Difference |
|---|---|---|---|
| 2026 YTD | 12.3% | -7.8% | +20.1% |
| 2025 | -10.0% | 7.7% | −17.6% |
| 2024 | 41.3% | 15.6% | +25.6% |
| 2023 | 31.6% | 26.5% | +5.1% |
| 2022 | -8.7% | 3.8% | −12.5% |
Benchmark proxy: Motilal Oswal Nifty 500 Index Fund (Direct plan NAV, price return), which carries its own costs. The first year starts from the first 31 December in the scheme's history.
| Period | Invested | Value | XIRR |
|---|---|---|---|
| 1 year | ₹1,20,000 | ₹1,30,552 | 16.7% |
| 3 years | ₹3,60,000 | ₹4,22,910 | 10.7% |
Uses this plan's NAVs; ignores stamp duty, exit loads and taxes. One historical path only — the interactive SIP analyzer shows outcomes across every start date.
| Scheme | Category | Correlation | 3Y CAGR |
|---|---|---|---|
| UTI - Healthcare Fund | Sectoral/Thematic | 0.97 | 21.4% |
| HDFC Pharma and Healthcare Fund | Sectoral/Thematic | 0.97 | 28.6% |
| LIC MF Healthcare Fund | Sectoral/Thematic | 0.97 | 19.4% |
| Tata India Pharma & Healthcare Fund | Sectoral/Thematic | 0.97 | 16.5% |
| Mirae Asset Healthcare Fund | Sectoral/Thematic | 0.97 | 20.0% |
| Kotak Healthcare Fund | Sectoral/Thematic | 0.96 | n/a |
- What is the latest NAV of ITI Pharma and Healthcare Fund?
- The NAV of the Regular plan (growth option) was ₹17.6281 on 1 Oct 2026, as published by AMFI.
- Which category is ITI Pharma and Healthcare Fund in?
- It is classified as Sectoral/Thematic in AMFI's daily NAV file; a Sectoral/Thematic scheme invests at least 80% in one sector or theme. MFIC compares it with 259 Sectoral/Thematic schemes (Regular plans).
- What returns has ITI Pharma and Healthcare Fund delivered?
- Over one year the NAV changed by 10.4%. The 3-year CAGR is 16.7% (category median 11.7%). Returns are after expenses and before tax. Past performance may or may not be sustained in future.
- How consistent have its 3-year returns been?
- Measuring a 3-year CAGR from every business day in its history, the median was 19.1%, the lowest was 15.2%, and 100% of 3-year periods ended with a gain. It was ahead of Nifty 500 (index-fund proxy) in 99% of those periods.
- What was the largest fall in ITI Pharma and Healthcare Fund's NAV?
- The largest peak-to-trough fall in its available history was 18.5%.
- How volatile is ITI Pharma and Healthcare Fund?
- Its annualised standard deviation of monthly returns over the last 36 months is 16.5%, which is below the Sectoral/Thematic category median of 16.7%.
- What would a monthly SIP in ITI Pharma and Healthcare Fund have grown to?
- A SIP of ₹10,000 on the first business day of each month for the last 3 years (36 instalments, ₹3,60,000 invested) would have been worth about ₹4,22,910 on 1 Oct 2026, an annualised return (XIRR) of 10.7%. This uses the Regular plan's NAVs, ignores taxes and exit loads, and past performance may or may not be sustained in future.
- What is the expense ratio (TER) of ITI Pharma and Healthcare Fund?
- The total expense ratio of the Regular plan is 2.59% a year, as disclosed to AMFI (median of Sectoral/Thematic Regular plans: 2.38%). It is already deducted from the NAV, so every return shown is after expenses.
- How large is ITI Pharma and Healthcare Fund?
- Assets under management of the whole scheme were ₹266 crore on 30 Sep 2026, as published by AMFI.
- What is the riskometer level of ITI Pharma and Healthcare Fund?
- AMFI lists the scheme's riskometer as “Very High”, and its benchmark's as “Very High”. The riskometer is a label of potential risk set under SEBI rules, not a forecast.
- What is the benchmark of ITI Pharma and Healthcare Fund and how has it compared?
- Its official benchmark is the NIFTY Healthcare TRI. Over 3 years AMFI reports a return of 16.7% for this plan against 19.0% for the benchmark total return index. Past performance does not indicate future results.
- How often has ITI Pharma and Healthcare Fund beaten its category?
- At 96% of the 23 month-ends compared over the last 10 years, its 3-year return was above the median of Sectoral/Thematic schemes (Regular plans); it was in the top quarter at 4% of them. A typical scheme would show about 50%.
- Who manages ITI Pharma and Healthcare Fund?
- According to its Scheme Summary Document, ITI Pharma and Healthcare Fund is managed by Animesh Singh (since 8 May 2026), Nilay Dalal (since 8 May 2026).
- What is the exit load of ITI Pharma and Healthcare Fund?
- As stated in its scheme documents: If redeemed/Switched out on or before 3 Months from the date of allotment; Exit Load is 0.50% Exit Load after completion of 3 months - NIL Check the latest Scheme Information Document before investing, as loads can change.
- What is the minimum investment in ITI Pharma and Healthcare Fund?
- The minimum application amount is ₹5,000. SIP details: SIP-Daily: Rs. 500/-/ Weekly and Monthly:Rs. 500/- or Rs. 1000/-, STP- Rs. 500/-, SWP- Rs. 1000/-.
- What is the difference between the Direct and Regular plans?
- Both plans hold the same portfolio; the Regular plan includes distribution costs in its expense ratio. Over one year the Direct plan's NAV changed by 12.4% and the Regular plan's by 10.4%. The Regular plan includes the services of a distributor.
Every Monday: this scheme's NAV, 1-month and 1-year return beside its category median, 3-year CAGR and how far it is below its peak. Add more schemes from their pages or from your MFIC watchlist. Free; unsubscribe from any email.